SurgLine International Inc. (PINK: SGLN), a distributor of high quality FDA approved medical and surgical products at discount prices, today, provided an update on its revenue pipeline.
CEO Thomas Toland said that following the acquisition of SurgLine Inc., the new company and its management team has invested significant amount of their time and effort in laying the groundwork for the company to operate.
The management team at SGLN focused on building long-term value and revenue for SGLN and its shareholders. Toland said that SGLN management has introduced its products and pricing to the acute care hospitals, hospital systems, the VA hospital system, surgery centers, health plans and others.
Toland added that SGLN is confident that with its current revenue pipeline of additional programs in process and previously executed agreements, it will meet the previously stated revenue goal by the end of this year.
SGLN shares are currently trading at $0.0004, unchanged from the previous trading session.
Recent Comments